- Home
- PRPO vs VRCA Comparison
PRPO vs VRCA Comparison
Compare PRPO & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- VRCA
- Stock Information
- Founded
- PRPO N/A
- VRCA 2013
- Country
- PRPO United States
- VRCA United States
- Employees
- PRPO N/A
- VRCA N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- VRCA Health Care
- Exchange
- PRPO Nasdaq
- VRCA Nasdaq
- Market Cap
- PRPO 32.4M
- VRCA 32.7M
- IPO Year
- PRPO N/A
- VRCA 2018
- Fundamental
- Price
- PRPO $20.50
- VRCA $3.84
- Analyst Decision
- PRPO
- VRCA Hold
- Analyst Count
- PRPO 0
- VRCA 2
- Target Price
- PRPO N/A
- VRCA N/A
- AVG Volume (30 Days)
- PRPO 11.3K
- VRCA 248.8K
- Earning Date
- PRPO 11-17-2025
- VRCA 11-06-2025
- Dividend Yield
- PRPO N/A
- VRCA N/A
- EPS Growth
- PRPO N/A
- VRCA N/A
- EPS
- PRPO N/A
- VRCA N/A
- Revenue
- PRPO $21,242,000.00
- VRCA $14,704,000.00
- Revenue This Year
- PRPO N/A
- VRCA $332.45
- Revenue Next Year
- PRPO N/A
- VRCA $12.85
- P/E Ratio
- PRPO N/A
- VRCA N/A
- Revenue Growth
- PRPO 27.05
- VRCA 5.72
- 52 Week Low
- PRPO $3.90
- VRCA $3.28
- 52 Week High
- PRPO $22.38
- VRCA $13.60
- Technical
- Relative Strength Index (RSI)
- PRPO 51.49
- VRCA 47.99
- Support Level
- PRPO $19.00
- VRCA $3.37
- Resistance Level
- PRPO $21.00
- VRCA $3.99
- Average True Range (ATR)
- PRPO 1.05
- VRCA 0.25
- MACD
- PRPO -0.16
- VRCA 0.06
- Stochastic Oscillator
- PRPO 27.44
- VRCA 73.24
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.